drugset
Drugs / LNTH-2403
last change Feb 2026 re-read 3 minutes ago

LNTH-2403

also known as 177Lu-DOTA-DUNP19

Monoclonal antibody targets LRRC15

Developed for
bone osteosarcoma
Investigated by
Lantheus Medical Imaging · Radiopharm Theranostics, Ltd

Trials 2

today NCT07357519 · Ph 1/2 NCT07272642 · Ph 1
2027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07272642 Jan 2026 → Aug 2027 expected colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma Radiopharm Theranostics, Ltd Not yet recruiting No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT07357519 Feb 2026 → Aug 2027 expected bone osteosarcoma Lantheus Medical Imaging Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as LNTH-2403 “LNTH-2403, a LRRC15-targeted 177Lutetium-labeled Monoclonal Antibody” NCT07357519 ↗
1

NCT07272642 ↗
Known as 177Lu-DOTA-DUNP19 “LNTH-2403 (177Lu-DOTA-DUNP19) is a lutetium-177 radiolabeled, fully humanized monoclonal antibody (mAb)” NCT07272642 ↗
Modality Monoclonal antibody “fully humanized monoclonal antibody (mAb)” NCT07272642 ↗
Target LRRC15 “targeting the LRRC15 epitope” NCT07272642 ↗